Literature DB >> 22796282

Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome.

Henrique Luiz Staub1, Maria Laura Bertolaccini, Munther A Khamashta.   

Abstract

The antiphospholipid syndrome (APS) is an acquired disorder characterized by arterial and/or venous thrombosis and pregnancy morbidity. In solid assays, sera from patients with APS usually react to negatively charged phospholipids (PL) and PL cofactors such as β2-glycoprotein I (β2GPI). Binding to neutral PL such as phosphatidylethanolamine (PE) is less common. PE is one of the main lipid components of the biological membranes, being mostly located in the inner leaflet. In 1989 we reported the first case of primary APS whereby a LA was accompanied not by an anticardiolipin antibody (aCL), but by an antibody to PE (aPE). In this review, we update the literature concerning the presence of aPE in patients with thromboembolic events and obstetric morbidity. We also discuss aPE as the sole antibody detected in many of these clinical circumstances. An eventual link of aPE antibodies with failure of in vitro fertilization is also considered as well as uncommon clinical associations of aPE that are also discussed.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22796282     DOI: 10.1016/j.autrev.2012.07.008

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  13 in total

Review 1.  Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

2.  Early endosome as a pathogenic target for antiphosphatidylethanolamine antibodies.

Authors:  Songwang Hou; Heike Fölsch; Ke Ke; Joan Cook Mills; Rosalind Ramsey-Goldman; Ming Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-11       Impact factor: 11.205

3.  The outcome of ELISA for antiphosphatidylethanolamine antibodies is dependent on the composition of phosphatidylethanolamine.

Authors:  Songwang Hou; Paul E Harper; Nathalie Bardin; Ming Zhao
Journal:  J Immunol Methods       Date:  2016-10-23       Impact factor: 2.303

4.  Presence of antiphospholipid antibody is a risk factor in thrombotic events in patients with antiphospholipid syndrome or relevant diseases.

Authors:  Koji Habe; Hideo Wada; Takeshi Matsumoto; Kohshi Ohishi; Makoto Ikejiri; Kimiko Matsubara; Tatsuhiko Morioka; Yuki Kamimoto; Tomoaki Ikeda; Naoyuki Katayama; Tsutomu Nobori; Hitoshi Mizutani
Journal:  Int J Hematol       Date:  2013-02-03       Impact factor: 2.490

5.  Influence of Phosphatidylethanolamine Concentration and Composition on the Detection of Antiphosphatidylethanolamine Antibodies by ELISA.

Authors:  Ke Ke; Zachariah I Strango; Paul E Harper; Ming Zhao
Journal:  J Clin Lab Anal       Date:  2016-04-07       Impact factor: 2.352

6.  Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative.

Authors:  Emmanuel Coloma Bazán; Carolina Donate López; Pedro Moreno Lozano; Ricard Cervera; Gerard Espinosa
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

Review 7.  Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay.

Authors:  Savino Sciascia; Simone Baldovino; Karen Schreiber; Laura Solfietti; Massimo Radin; Maria J Cuadrado; Elisa Menegatti; Doruk Erkan; Dario Roccatello
Journal:  Clin Mol Allergy       Date:  2016-07-15

8.  Cerebral venous thrombosis revealing primary sjögren syndrome: report of 2 cases.

Authors:  A Mercurio; M Altieri; V M Saraceni; T Paolucci; G L Lenzi
Journal:  Case Rep Med       Date:  2013-01-03

Review 9.  Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers.

Authors:  Pier Luigi Meroni; Cecilia Beatrice Chighizola; Francesca Rovelli; Maria Gerosa
Journal:  Arthritis Res Ther       Date:  2014       Impact factor: 5.156

10.  Antiphospholipid antibodies in localized scleroderma: the potential role of screening tests for the detection of antiphospholipid syndrome.

Authors:  Anna Lis-Święty; Ligia Brzezińska-Wcisło; Hubert Arasiewicz; Beata Bergler-Czop
Journal:  Postepy Dermatol Alergol       Date:  2014-04-22       Impact factor: 1.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.